Prognosis of RUNX1-RUNX1T1 Rearrangement in Newly Diagnosed Acute Myeloid Leukemia Patients
DOI:
https://doi.org/10.51985/JBUMDC2023239Keywords:
Acute myeloid leukemia, AML with t (8;21), Complete Remission, Prognosis, RUNX1-RUNX1T1Abstract
Objective: To compare the clinical-hematological (including laboratory and morphological) parameters of newly diagnosed AML patients with RUNX1-RUNX1T1 rearrangement before and after induction therapy.
Study Design and Setting: This is a cross-sectional study, Department of Hematology, Armed Forces Institute of Pathology (AFIP), Rawalpindi from December 2021 to December 2022.
Methodology: 64 newly diagnosed patients with de novo t (8;21) AML were included. The RUNX1-RUNX1T1 fusion gene was detected using real-time reverse transcriptase polymerase chain reaction (RT-PCR); while t(8;21) was identified through chromosomal/cytogenetic analysis. All the clinical parameters, laboratory variables, blast percentages, and morphological parameters of newly diagnosed AML RUNX1-RUNX1T1 patients were compared before and after therapy. AML induction regimen included the following drugs: cytarabine along daunorubicin. Assessment of these patients was carried out four weeks after induction therapy.
Results: The patients' mean age was 60 (ranging from 14 to 85 years), with 46 males and 18 females. Statistical significance was observed in TLC (p-value < 0.001), Hb (p= 0.001), and platelet count(p=0.001) levels. After treatment, the blast size in peripheral blood was reduced to zero and both Auer rods and abnormal granules were absent in bone marrow blasts of patients. The average percentage of eosinophilia decreased from 8.52±1.76 before treatment to 2.42±1.79 after treatment. Conclusions: Our study concluded that the treatment approach(cytarabine along with daunorubicin or idarubicin) for
patients with RUNX1-RUNX1T1 AML resulted in improved blood counts, reduced blast cells, Auer rods, and abnormal granules; with a higher rate of complete remission and a lower incidence of relapse.
References
Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM.
Epidemiology of acute myeloid leukemia: Recent progress
and enduring challenges. Blood reviews. 2019;36:70-87.
https://doi.org/10.1016/j.blre.2019.04.005
Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT,
Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen
JJ, Scheinberg DA. Acute myeloid leukemia. Nat Rev Dis
Primers. 2016;2(1):1-22. https://doi.org/10.1038 /nrdp.2016.10
Foucar K, Hsi ED, Wang SA, Rogers HJ, Hasserjian RP, Bagg
A, George TI, Bassett Jr RL, Peterson LC, Morice WG, Arber
DA. Concordance among hematopathologists in classifying
blasts plus promonocytes: a bone marrow pathology group
study. Int J Lab Hematol. 2020;42(4):418-22. https://doi.
org/10.1111/ijlh.13212
Gudipati M, Butler M, Koka R, Baer MR, Ning Y. Fusion
Gene-Based Classification of Variant Cytogenetic
Rearrangements in Acute Myeloid Leukemia. Genes.
;14(2):396. https://doi.org/10.3390/genes14020396
Weinberg OK, Porwit A, Orazi A, Hasserjian RP, Foucar K,
Duncavage EJ, Arber DA. The International Consensus
Classification of acute myeloid leukemia. Virchows Archiv.
;482(1):27-37. https://doi.org/10.1007/s00428-022-03430-
Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML,
Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce
SR, Estey EH. The clinical spectrum of adult acute myeloid
leukaemia is associated with core binding factor translocations.
Br J Haematol. 2006;135(2):165-73. https://doi.org/ 10.1111/
j.1365-2141.2006.06276.x
Al-Harbi S, Aljurf M, Mohty M, Almohareb F, Ahmed SO.
An update on the molecular pathogenesis and potential
therapeutic targeting of AML with t (8; 21)(q22; q22. 1);
RUNX1-RUNX1T1. Blood advances. 2020;4(1):229-38.
https://doi.org/10.1182/bloodadvances.2019000168
Raj TA, Gopinath P, Raj JG, Narayanan G, Nair SG, Philip
DS, Raveendran S, Geetha P, Sreedharan H. Acute myeloid
leukemia patients with variant or unusual translocations
involving chromosomes 8 and 21–A comprehensive
cytogenetic profiling of three cases with review of the literature.
J Cancer Ther Res. 2022;18(3):697-703. DOI: 10.4103 /jcrt.
jcrt_190_21
Gustafson SA, Lin P, Chen SS, Chen L, Abruzzo LV, Luthra
R, Medeiros LJ, Wang SA. Therapy-related acute myeloid
leukemia with t (8; 21)(q22; q22) shares many features with
de novo acute myeloid leukemia with t (8; 21)(q22; q22) but
does not have a favorable outcome. Am J Clin Pathol.
;131(5):647-55. https://doi.org/10.1309 /AJCP5ETHD
XO6NCGZ
Rücker FG, Agrawal M, Corbacioglu A, Weber D, KappSchwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M,
Lübbert M, Koller E. Measurable residual disease monitoring
in acute myeloid leukemia with t (8; 21)(q22; q22. 1): results
from the AML Study Group. Blood, Am. J. Hematol.
;134(19):1608-18. https://doi.org/10.1182 /blood.
Foucar K, Hsi ED, Wang SA, Rogers HJ, Hasserjian RP, Bagg
A, George TI, Bassett Jr RL, Peterson LC, Morice WG, Arber
DA. Concordance among hematopathologists in classifying
blasts plus promonocytes: a bone marrow pathology group
study. International Journal of Laboratory Hematology.
;42(4):418-22. https://doi.org/10.1111/ijlh.13212
Suguna E, Farhana R, Kanimozhi E, Kumar PS,
Kumaramanickavel G, Kumar CS. Acute myeloid leukemia:
diagnosis and management based on current molecular genetics
approach. Cardiovascular & Haematological Disorders-Drug
Targets (Formerly Current Drug Targets-Cardiovascular &
Hematological Disorders). 2018;18(3):199-207. https://doi.org/
2174/1871529X18666180515130136
Li X, Liu G. Acute Myeloid Leukemias with Variant RUNX1::
RUNX1T1: Report of Three Cases. Hematop.2023;8(1).
https://journals.librarypublishing.arizona.edu/hemepath/arti
cle/id/5668/
Vasu S, Kohlschmidt J, Mrózek K, Eisfeld AK, Nicolet D,
Sterling LJ, Becker H, Metzeler KH, Papaioannou D, Powell
BL, Kolitz JE. Ten-year outcome of patients with acute
myeloid leukemia not treated with allogeneic transplantation
in first complete remission. Blood adv. 2018;2(13):1645-
https://doi.org/10.1182/bloodadvances.2017015222
Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf
S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn
JY. Addition of gemtuzumab ozogamicin to induction
chemotherapy in adult patients with acute myeloid leukaemia:
a meta-analysis of individual patient data from randomized
controlled trials. Lancet Oncol. 2014;15(9):986-96.
https://doi.org/10.1016/S1470-2045(14)70281-5
Butler E, Ludwig K, Pacenta HL, Klesse LJ, Watt TC, Laetsch
TW. Recent progress in the treatment of cancer in children.
CA: a Cancer Journal for Clinicians. 2021;71(4):315-32.
https://doi.org/10.3322/caac.21665
Wilde L, Cooper J, Wang ZX, Liu J. Clinical, Cytogenetic,
and Molecular Findings in Two Cases of Variant t (8; 21)
Acute Myeloid Leukemia (AML). Front Oncol. 2019;9:1016.
https://doi.org/10.3389/fonc.2019.01016
Kim KH, Kim TG, Han JY, Kim JM, Kim JS, Kim HJ, Lee
YH, Lee EY. Cytogenetical, Morphological, and
Immunophenotypical Characteristics of Myeloid Myeloid
Malignancies with t (8; 21). Korean J Hematol. 1999;34(1):18-
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S,
Goldstone AH, Wheatley K, Harrison CJ, Burnett AK, National
Cancer Research Institute Adult Leukaemia Working Group.
Refinement of cytogenetic classification in acute myeloid
leukemia: determination of prognostic significance of rare
recurring chromosomal abnormalities among 5876 younger
adult patients treated in the United Kingdom Medical Research
Council trials. Blood, Am. J. Hematol. 2010;116(3):354-65
https://doi.org/10.1182/blood-2009-11-254441
Lin P, Chen L, Luthra R, Konoplev SN, Wang X, Medeiros
LJ. Acute myeloid leukemia harboring t (8; 21)(q22; q22): a
heterogeneous disease with poor outcome in a subset of
patients unrelated to secondary cytogenetic aberrations. Mod
Pathol. 2008;21(8):1029-36. https://doi.org/ 10.1038/
modpathol.2008.92
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Halima Babar, Hamid Saeed Malik, Muhammad Umar, Zahra Tasleem, Nazish Tahir
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
